GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Immunovia AB (OSTO:IMMNOV) » Definitions » Institutional Ownership

Immunovia AB (OSTO:IMMNOV) Institutional Ownership : 2.21% (As of May. 19, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Immunovia AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Immunovia AB's institutional ownership is 2.21%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Immunovia AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Immunovia AB's Float Percentage Of Total Shares Outstanding is 0.00%.


Immunovia AB Institutional Ownership Historical Data

The historical data trend for Immunovia AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovia AB Institutional Ownership Chart

Immunovia AB Historical Data

The historical data trend for Immunovia AB can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 3.44 2.39 1.85 1.85 1.84 2.10 2.21 2.21 2.21 2.21

Immunovia AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Immunovia AB (OSTO:IMMNOV) Business Description

Traded in Other Exchanges
Address
Medicon Village, Scheelevagen 8, Lund, SWE, 223 63
Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The group's intangible and tangible assets are in Sweden, in the United States and in Germany.

Immunovia AB (OSTO:IMMNOV) Headlines

No Headlines